These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 26593949)

  • 41. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer.
    Ishibashi Y; Tobisawa Y; Hatakeyama S; Ohashi T; Tanaka M; Narita S; Koie T; Habuchi T; Nishimura S; Ohyama C; Yoneyama T
    Prostate; 2014 Nov; 74(15):1521-9. PubMed ID: 25154914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches.
    Jefferi NES; Shamhari A'; Noor Azhar NKZ; Shin JGY; Kharir NAM; Azhar MA; Hamid ZA; Budin SB; Taib IS
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth.
    Jiang N; Ke B; Hjort-Jensen K; Iglesias-Gato D; Wang Z; Chang P; Zhao Y; Niu X; Wu T; Peng B; Jiang M; Li X; Shang Z; Wang Q; Chang C; Flores-Morales A; Niu Y
    Oncotarget; 2017 Dec; 8(70):115054-115067. PubMed ID: 29383141
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
    Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
    Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.
    Armstrong CM; Gao AC
    Am J Clin Exp Urol; 2015; 3(2):64-76. PubMed ID: 26309896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells.
    Khurana N; Chandra PK; Kim H; Abdel-Mageed AB; Mondal D; Sikka SC
    Antioxidants (Basel); 2020 Jan; 9(1):. PubMed ID: 31940946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
    Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
    Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.
    Li JR; Chiu KY; Wang SS; Yang CK; Chen CS; Ho HC; Hung CF; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Chang CH; Hsu CY; Ou YC
    Front Pharmacol; 2017; 8():836. PubMed ID: 29213237
    [No Abstract]   [Full Text] [Related]  

  • 53. Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.
    Lavaud P; Dumont C; Thibault C; Albiges L; Baciarello G; Colomba E; Flippot R; Fuerea A; Loriot Y; Fizazi K
    Ther Adv Med Oncol; 2020; 12():1758835920978134. PubMed ID: 33488778
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging molecularly targeted therapies in castration refractory prostate cancer.
    Patel JC; Maughan BL; Agarwal AM; Batten JA; Zhang TY; Agarwal N
    Prostate Cancer; 2013; 2013():981684. PubMed ID: 23819055
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New drugs in prostate cancer.
    Yoo S; Choi SY; You D; Kim CS
    Prostate Int; 2016 Jun; 4(2):37-42. PubMed ID: 27358841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of 11-oxygenated androgens in prostate cancer.
    Snaterse G; Hofland J; Lapauw B
    Endocr Oncol; 2023 Jan; 3(1):e220072. PubMed ID: 37434644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Loss of AR-regulated AFF3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating ACSL4 based on single-cell sequencing analysis.
    Fan A; Li Y; Zhang Y; Meng W; Pan W; Chen M; Ma Z; Chen W
    Apoptosis; 2024 Oct; 29(9-10):1679-1695. PubMed ID: 38478171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells.
    Du Z; Li L; Sun W; Zhu P; Cheng S; Yang X; Luo C; Yu X; Wu X
    Front Oncol; 2021; 11():607291. PubMed ID: 33791203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A changing landscape in castration-resistant prostate cancer treatment.
    Felici A; Pino MS; Carlini P
    Front Endocrinol (Lausanne); 2012; 3():85. PubMed ID: 22826702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interplay of Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 3 in Prostate Cancer: Beyond Androgen Receptor Transactivation.
    Lin SR; Yeh HL; Liu YN
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.